D Kupka, D Sibbing - Korean Circulation Journal, 2018 - synapse.koreamed.org
Dual antiplatelet therapy (DAPT)—a combination of a P2Y12 receptor inhibitor and aspirin— has revolutionized antithrombotic treatment. Potent P2Y12 inhibitors such as prasugrel and …
D Sibbing, L Gross, D Trenk… - European Heart …, 2018 - academic.oup.com
Aims Guided de-escalation of P2Y12-inhibitor treatment was recently identified as an effective alternative treatment strategy in acute coronary syndrome (ACS) patients …
L Gross, D Trenk, C Jacobshagen… - Thrombosis and …, 2018 - thieme-connect.com
Background Phenotype-guided de-escalation (PGDE) of P2Y 12-inhibitor treatment with an early switch from prasugrel to clopidogrel was identified as an effective alternative treatment …
D Kupka, D Sibbing - Expert opinion on drug metabolism & …, 2018 - Taylor & Francis
Introduction: P2Y12 inhibitors are a critical component of dual antiplatelet therapy (DAPT), which is the superior strategy to prevent arterialthrombosis in patients with acute coronary …
S Landry, JF Tanguay, M Lordkipanidzé - Platelets, 2018 - Taylor & Francis
Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is currently the standard of care for the prevention of ischemic events in patients with acute coronary …
A Tello-Montoliu, J Rivera, D Hernández… - Circulation …, 2018 - jstage.jst.go.jp
Background: Prasugrel has been shown to provide more potency and less variability than clopidogrel, but its potential temporal variability has not been described. Methods and …
LP de Carvalho, A Fong, R Troughton… - Thrombosis and …, 2018 - thieme-connect.com
Studies on platelet reactivity (PR) testing commonly test PR only after percutaneous coronary intervention (PCI) has been performed. There are few data on pre-and post-PCI …
YS Chatzizisis, C Stefanadis - Journal of the American College of …, 2018 - jacc.org
—Hippocrates, 460 to 370 BC (1) P2Y12 receptors on platelet membrane are key modulators of platelet aggregation and thrombosis in acute coronary syndromes (2). Oral …
Background: The point-of-care platelet function test Plateletworks® has been shown to identify patients with high platelet aggregation despite P2Y12 inhibition, also known as high …